The HemOnc Pulse cover image

The HemOnc Pulse

Discussing the Role of MRD in CLL With Talal Hilal, MD

May 16, 2024
Dr. Talal Hilal from Mayo Clinic discusses measuring MRD in CLL with Chadi Nabhan. They explore MRD detection methods, its role in treatment decisions, challenges with doublet therapies, and the controversy around MRD in CLL.
21:38

Episode guests

Podcast summary created with Snipd AI

Quick takeaways

  • Undetectable MRD levels in CLL may indicate a deeper remission and potentially better outcomes.
  • Clinical trials using MRD-guided treatment decisions in CLL have shown improved survival rates.

Deep dives

Understanding Measurable Residual Disease in CLL

Measurable Residual Disease (MRD) in Chronic Lymphocytic Leukemia (CLL) refers to cancer cells that were previously undetectable but can now be seen using advanced techniques like flow cytometry and next-generation sequencing. Achieving undetectable MRD levels may indicate a deeper remission, potentially leading to better outcomes. While the importance of MRD in CLL treatment is debated due to the indolent nature of the disease, eradicating even the last cancer cell could theoretically result in a cure.

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode